Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy.
Cardiac Amyloidosis
Diagnosis
Prognosis
Transthyretin
Treatment
Journal
Global heart
ISSN: 2211-8179
Titre abrégé: Glob Heart
Pays: England
ID NLM: 101584391
Informations de publication
Date de publication:
2023
2023
Historique:
received:
20
09
2023
accepted:
20
10
2023
medline:
1
12
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Transthyretin cardiac amyloidosis (ATTR-CA) has been traditionally considered a rare and inexorably fatal condition. ATTR-CA now is an increasingly recognised cause of heart failure and mortality worldwide with effective pharmacological treatments. Advances in non-invasive diagnosis, coupled with the development of effective treatments, have transformed the diagnosis of ATTR-CA, which is now possible without recourse to endomyocardial biopsy in around 70% of cases. Many patients are now diagnosed at an earlier stage. Echocardiography and cardiac magnetic resonance have enabled identification of patients with possible ATTR-CA and more accurate prognostic stratification. Therapies able to slow or halt ATTR-CA progression and increase survival are now available and there is also evidence that patients may benefit from specific conventional heart failure medications. A wide horizon of possibilities is unfolding and awaits discovery.
Identifiants
pubmed: 38028963
doi: 10.5334/gh.1275
pmc: PMC10668877
doi:
Substances chimiques
Prealbumin
0
Types de publication
Editorial
Langues
eng
Sous-ensembles de citation
IM
Pagination
63Informations de copyright
Copyright: © 2023 The Author(s).
Déclaration de conflit d'intérêts
The authors have no competing interests to declare.
Références
Circulation. 2016 Jun 14;133(24):2404-12
pubmed: 27143678
Eur J Heart Fail. 2020 Mar;22(3):507-515
pubmed: 31975495
J Am Coll Cardiol. 2022 Apr 5;79(13):1288-1303
pubmed: 35361352
N Engl J Med. 2023 Jun 8;388(23):2199-2201
pubmed: 37285532
Eur J Heart Fail. 2023 Apr;25(4):515-524
pubmed: 36644836
Cardiovasc Res. 2023 Feb 3;118(18):3517-3535
pubmed: 35929637
Eur J Prev Cardiol. 2023 Feb 14;30(3):e4-e6
pubmed: 36256685
N Engl J Med. 2023 Jul 20;389(3):239-250
pubmed: 37212440
Eur J Intern Med. 2020 Dec;82:7-15
pubmed: 33032855
Eur Heart J. 2021 Apr 21;42(16):1554-1568
pubmed: 33825853
JACC Basic Transl Sci. 2019 Jun 24;4(3):438-448
pubmed: 31312767
Eur Heart J. 2022 Dec 1;43(45):4722-4735
pubmed: 36239754
N Engl J Med. 2018 Sep 13;379(11):1007-1016
pubmed: 30145929
Heart Fail Rev. 2015 Mar;20(2):117-24
pubmed: 25758359
Eur J Heart Fail. 2022 Dec;24(12):2355-2363
pubmed: 36575133
Circulation. 2022 Nov 29;146(22):1657-1670
pubmed: 36325894
N Engl J Med. 2021 Aug 5;385(6):493-502
pubmed: 34215024
ESC Heart Fail. 2022 Feb;9(1):751-760
pubmed: 34755478
Eur J Heart Fail. 2022 Sep;24(9):1700-1712
pubmed: 35779241
JACC Cardiovasc Imaging. 2019 May;12(5):823-833
pubmed: 29680336
JACC Cardiovasc Imaging. 2021 Jan;14(1):189-199
pubmed: 33129740
Alzheimers Dement (N Y). 2023 Mar 20;9(1):e12377
pubmed: 36949897